Ascendis Pharma A/S (ASND)
NASDAQ:ASND
Want to see ASND full AI Analyst Report?
Total Valuation
Ascendis Pharma has a market cap or net worth of $14.81B. The enterprise value is $12.20B.
Market Cap$14.81B
Enterprise Value$12.20B
Share Statistics
Ascendis Pharma has 62,376,846 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding62,376,846
Owned by Insiders<0.01%
Owned by Institutions―
Financial Efficiency
Ascendis Pharma’s return on equity (ROE) is 1.35 and return on invested capital (ROIC) is -18.19%.
Return on Equity (ROE)1.35
Return on Assets (ROA)-0.17
Return on Invested Capital (ROIC)-18.19%
Return on Capital Employed (ROCE)-0.56
Revenue Per Employee680.15K
Profits Per Employee-215.37K
Employee Count1,017
Asset Turnover0.53
Inventory Turnover0.34
Valuation Ratios
The current PE Ratio of Ascendis Pharma is 23.4. Ascendis Pharma’s PEG ratio is 1.13.
PE Ratio23.4
PS Ratio15.90
PB Ratio-67.58
Price to Fair Value-67.58
Price to FCF252.17
Price to Operating Cash Flow205.68
PEG Ratio1.13
Income Statement
In the last 12 months, Ascendis Pharma had revenue of 691.71M and earned -219.03M in profits. Earnings per share was -3.62.
Revenue691.71M
Gross Profit588.53M
Operating Income-130.89M
Pretax Income-204.26M
Net Income-219.03M
EBITDA-113.90M
Earnings Per Share (EPS)-3.62
Cash Flow
In the last 12 months, operating cash flow was 57.63M and capital expenditures -15.53M, giving a free cash flow of 42.11M billion.
Operating Cash Flow57.63M
Free Cash Flow42.11M
Free Cash Flow per Share0.68
Dividends & Yields
Ascendis Pharma pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.67
52-Week Price Change27.56%
50-Day Moving Average233.00
200-Day Moving Average216.12
Relative Strength Index (RSI)40.43
Average Volume (3m)704.49K
Important Dates
Ascendis Pharma upcoming earnings date is Aug 6, 2026, After Close (Confirmed).
Last Earnings DateMay 7, 2026
Next Earnings DateAug 6, 2026
Ex-Dividend Date―
Financial Position
Ascendis Pharma as a current ratio of 1.04, with Debt / Equity ratio of 183.75%
Current Ratio1.04
Quick Ratio0.76
Debt to Market Cap0.08
Net Debt to EBITDA-2.24
Interest Coverage Ratio-1.69
Taxes
In the past 12 months, Ascendis Pharma has paid 14.78M in taxes.
Income Tax14.78M
Effective Tax Rate-0.07
Enterprise Valuation
Ascendis Pharma EV to EBITDA ratio is -98.82, with an EV/FCF ratio of 258.03.
EV to Sales16.27
EV to EBITDA-98.82
EV to Free Cash Flow258.03
EV to Operating Cash Flow217.41
Balance Sheet
Ascendis Pharma has $573.42M in cash and marketable securities with $897.60M in debt, giving a net cash position of -$324.18M billion.
Cash & Marketable Securities$573.42M
Total Debt$897.60M
Net Cash-$324.18M
Net Cash Per Share-$5.20
Tangible Book Value Per Share-$2.75
Margins
Gross margin is 88.17%, with operating margin of -18.92%, and net profit margin of -31.67%.
Gross Margin88.17%
Operating Margin-18.92%
Pretax Margin-29.53%
Net Profit Margin-31.67%
EBITDA Margin-16.47%
EBIT Margin-18.92%
Analyst Forecast
The average price target for Ascendis Pharma is $301.75, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target$301.75
Price Target Upside23.43% Upside
Analyst ConsensusStrong Buy
Analyst Count14
Revenue Growth Forecast155.14%
EPS Growth Forecast―